scholarly journals CSF Myelin Basic Protein Levels in Acute Optic Neuritis and Multiple Sclerosis

Author(s):  
K.G. Warren ◽  
Ingrid Catz ◽  
T.A. McPherson

SUMMARY:Normal CSF-MBP levels as determined by a RIA were <6.2 ng/ml CSF (mean 3.9). Eighty percent of patients with acute optic neuritis have CSF-MBP levels greater than 6.2 ng/ml (mean 7.6 ng/ml CSF). Five of 7 patients with acute internuclear ophthalmoplegia due to an initial exacerbation of demyelination have CSF-MBP levels above 6.2 ng/ml (mean 6.8 ng/ml). Fifty percent of MS patients with chronic progressive disease have CSF-MBP levels above 6.2 ng/ml (mean 6.7 ng/ml). MS patients experiencing monosymptomatic exacerbations show elevated CSF-MBP levels in 75% of cases (mean 8.2 ng/ml). MS patients experiencing polysymptomatic exacerbations show significantly higher levels of CSF-MBP (mean 22.3 ng/ml) than the patients with monosymptomatic exacerbations. Ninety-five percent of MS patients experiencing polysymptomatic exacerbations have elevated levels of CSF-MBP.

2005 ◽  
Vol 11 (4) ◽  
pp. 492-494 ◽  
Author(s):  
E T Lim ◽  
T Berger ◽  
M Reindl ◽  
C M Dalton ◽  
K Fernando ◽  
...  

This study investigates whether the presence of serum and plasma anti-myelin oligodendrocyte glycoprotein (MOG) and anti-myelin basic protein (MBP) in patients presenting with a clinically isolated syndrome compatible with demyelination (CIS) predicts early conversion to multiple sclerosis (MS). Forty-seven patients with CIS (46 with optic neuritis) had anti-MOG and anti-MBP antibodies analysed at baseline, and clinical and magnetic resonance imaging assessments. There was no evidence that the MS status based on either the McDonald or Poser criteria relates to the antibody status.


1995 ◽  
Vol 38 (6) ◽  
pp. 943-950 ◽  
Author(s):  
F. Sellebjerg ◽  
H. O. Madsen ◽  
J. L. Frederiksen ◽  
L. P. Ryder ◽  
A. Svejgaard

Author(s):  
K.G. Warren ◽  
P.A. Gordon ◽  
T.A. McPherson

SUMMARY:A 17-year old female with “malignant” multiple sclerosis died 45 weeks after the onset of the disease. Postmortem examination confirmed the clinical diagnosis of multiple sclerosis. After 30 weeks of rapid clinical progression, the patient was treated with two courses of plasma exchange therapy without immunosuppression. This form of therapy caused a drop in cerebrospinal fluid myelin basic protein levels in one instance, but not in another. Controlled clinical trials are required to determine whether plasma exchange therapy is of value in the management of patients with multiple sclerosis, and the monitoring of cerebrospinal fluid myelin basic protein, if elevated, may be one useful marker to follow as part of these studies.


1994 ◽  
Vol 39 (6) ◽  
pp. 575-580 ◽  
Author(s):  
F. SELLEBJERG ◽  
J. L. FREDERIKSEN ◽  
T. OLSSON ◽  
H. LINK ◽  
H. O. MADSEN ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document